Profil
Naozumi Harada is the founder who currently holds the position of Representative Director & Chief Technology Officer at United Immunity Co. Ltd., which is founded in 2017.
Aktive Positionen von Naozumi Harada
| Unternehmen | Position | Beginn |
|---|---|---|
United Immunity Co. Ltd.
 United Immunity Co. Ltd. Pharmaceuticals: MajorHealth Technology United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages. | Gründer | 27.11.2017 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
United Immunity Co. Ltd.
United Immunity Co. Ltd. Pharmaceuticals: MajorHealth Technology United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages. | Health Technology |
